Evotec achieves first milestones in multi-target deal with UCB
Evotec AG announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.
The milestones were achieved upon the progression of certain projects into hit-to-lead and into lead optimisation.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: 'We are delighted that the project teams at UCB and Evotec have met these important milestones in the collaboration. The progress in this collaboration is a testament to the way scientists from both companies have worked together in a true partnership.'
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.